Reloxin: When?

The FDA had previously delayed the release of Reloxin, a Botox analog, because of administrative issues. Medicis, the US company that will be distributing Reloxin, had filed additional paperwork with the FDA detailing its plan for follow up of adverse events. The FDA was supposed to give Medicis an answer this month, but there has been no announcement forthcoming. The reasons are unclear, at this point.

Silhouette: Threadlift Revisited?

For many people it has long been a goal to achieve at least some of the benefits of a face-lift without sognificant surgery or downtime. The tightening of tissues in a face-lift or MACS-lift is achieved by using sutures to elevate the deeper tissues (SMAS) and the skin comes along for the ride. For a number of years surgeons have explored the idea of inserting a suture through the skin, hooking and tightening the deeper tissues and burying the tied ends of the sutures under the skin.

CO2 Fractional Lasers: Home Run or Hype?

The first of the fractional lasers was the Fraxel 750 which has evolved into the Fraxel Restore. This laser was clearly a significant advance over previous lasers, particularly in treating skin discoloration and acne scarring. It also helped lines, wrinkles and skin texture, but the improvement was not nearly so dramatic. The next advance, which was supposed to improve wrinkling as well as do everything that the Fraxel Restore could do, was the fractional CO2 laser, the application of the fractionated concept to the CO2 laser. The original CO2 laser was the most effective resurfacing laser, but one that, at times, produced unwanted side effects.